Ameriprise Financial Inc Ardelyx, Inc. Transaction History

Ameriprise Financial Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.89 - $9.31 $82,065 - $129,716	13,933 New	13,933 $103,000
Q4 2023 Feb 14, 2024	SELL	$3.29 - $6.64 $3.14 Million - $6.34 Million	-954,263 Reduced 98.59%	13,612 $84,000
Q3 2023 Nov 14, 2023	BUY	$3.3 - $4.83 $1.51 Million - $2.21 Million	458,151 Added 89.88%	967,875 $3.95 Million
Q2 2023 Aug 14, 2023	BUY	$3.23 - $4.95 $1.61 Million - $2.47 Million	499,511 Added 4890.93%	509,724 $1.73 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $27,370 - $48,920	10,213 New	10,213 $48,000
Q2 2022 Aug 15, 2022	SELL	$0.51 - $1.17 $7,639 - $17,526	-14,980 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.65 - $1.18 $9,737 - $17,676	14,980 New	14,980 $17,000
Q4 2021 Feb 14, 2022	SELL	$0.86 - $1.7 $12,904 - $25,508	-15,005 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $3,829 - $24,632	3,015 Added 25.15%	15,005 $20,000
Q2 2021 Aug 16, 2021	BUY	$6.55 - $8.98 $78,534 - $107,670	11,990 New	11,990 $91,000
Q1 2019 May 15, 2019	SELL	$1.88 - $3.35 $33,700 - $60,052	-17,926 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $1.04 Million - $2.61 Million	-627,589 Reduced 97.22%	17,926 $32,000
Q3 2018 Nov 14, 2018	BUY	$3.75 - $4.65 $113,396 - $140,611	30,239 Added 4.91%	645,515 $2.81 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $628,112 - $984,608	169,760 Added 38.1%	615,276 $2.28 Million
Q1 2018 May 15, 2018	BUY	$5.05 - $7.9 $11,110 - $17,380	2,200 Added 0.5%	445,516 $2.25 Million
Q4 2017 Feb 12, 2018	BUY	$4.85 - $7.8 $2.15 Million - $3.46 Million	443,316	443,316 $2.93 Million

219

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.